• Smith, RA, Miller, T, Cleveland, D, Bennett, F. Development of a Molecular Therapy for the SOD1 Familial Variant of ALS. Neurotherapeutics in the Era of Translational Medicine, Smith RA, Kaspar BK, Svendsen CN (eds.). Elsevier Academic Press; 2021.

• Smith, RA, Kaye, R, Yakatan, G. Repurposing FDA-Approved Pharmaceuticals: The Development of Nuedexta. Neurotherapeutics in the Era of Translational Medicine, Smith RA, Kaspar BK, Svendsen CN (eds.). Elsevier Academic Press; 2021.

• Sampath, R, Guler, M, Smith, RA. Bioethics in the Era of Translational Medicine. Neurotherapeutics in the Era of Translational Medicine, Smith RA, Kaspar BK, Svendsen CN (eds.). Elsevier Academic Press; 2021.

• Green JR, Allison KM, Cordella C, et al. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis. Br J Clin Pharmacol. 2018;84(12):2849-2856

• Smith RA, Macklin EA, Myers KJ, et al. Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale). Eur J Neurol. 2018;25(7):907-e66. 

• Smith R, Pioro E, Myers K, et al. Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics. 2017;14(3):762-772.

• Smith R, Myers K, Ravits J, Bowser R. Amyotrophic lateral sclerosis: Is the spinal fluid pathway involved in seeding and spread?. Med Hypotheses. 2015;85(5):576-583. 

• Meyer K, Ferraiuolo L, Miranda CJ, et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci U S A. 2014;111(2):829-832.

• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435-442.

• Sea K, Gowing G, Joyce N, et al. ALS in California: a report from the First Annual California ALS Research Summit. Neurodegen Dis Manag. 2011;1(4):281-284.

• Benson MD, Smith RA, Hung G, et al. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid. 2010;17(2):43-49. 

• Boyajian RA, Amo C, Otis SM, Romine JS, Smith RA. Magnetic source imaging of cortical dysfunction in amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2008;87(6):427-437. 

• Miller TM, Smith RA, Kordasiewicz H, Kaspar BK. Gene-Targeted Therapies for the Central Nervous System. Arch Neurol. 2008;65(4):447–451. 

• Miller TM, Smith RA, Cleveland DW. Amyotrophic lateral sclerosis and gene therapy. Nat Clin Pract Neurol. 2006;2(9):462-463.

• Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59(5):780-787.

• Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116(8):2290-2296. 

• Smith RA. Dextromethorphan/quinidine: a novel dextromethorphan product for the treatment of emotional lability. Expert Opin Pharmacother. 2006;7(18):2581-2598. 

• Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63(8):1364-1370.

• Smith RA, Berg JE, Pope LE, Callahan JD, Wynn D, Thisted RA. Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler. 2004;10(6):679-685.

• Smith RA, Berg JE, Pope LE, Thisted RA. Measuring pseudobulbar affect in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5 Suppl 1:99-102. 

• Wilson JM, Khabazian I, Wong MC, et al. Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour. Neuromolecular Med. 2002;1(3):207-221. 

• Armon C, Graves MC, Moses D, et al. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2000;23(6):874-882. 

• Smith RA. Effects of the early diagnosis of amyotrophic lateral sclerosis on the patient: disadvantages. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1 Suppl 1:S75-S77. 

• A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology. 1999;52(7):1427-1433. doi:10.1212/wnl.52.7.1427

• Smith RA, Licht J. Neuromuscular Disease. In: Bone RC, ed. Current Practice of Medicine. Philadelphia: Current Medicine, Inc.; 1996:807-817.

• Wilson DB, Golding AB, Smith RA, et al. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. J Neuroimmunol. 1997;76(1-2):15-28. 

• Moore SR, Gresham LS, Bromberg MB, Kasarkis EJ, Smith RA. A self report measure of affective lability. J Neurol Neurosurg Psychiatry. 1997;63(1):89-93. 

• Gold DP, Smith RA, Golding AB, et al. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide. J Neuroimmunol. 1997;76(1-2):29-38. 

• Feenberg AL, Licht JM, Kane KP, Moran K, Smith RA. The online patient meeting. J Neurol Sci. 1996;139 Suppl:129-131. 

• Smith RA, Balis FM, Ott KH, Elsberry DD, Sherman MR, Saifer MG. Pharmacokinetics and tolerability of ventricularly administered superoxide dismutase in monkeys and preliminary clinical observations in familial ALS. J Neurol Sci. 1995;129 Suppl:13-18.

• Smith RA, Licht JM, Manley PE, Girten B, Tuttle R. Testing the Limits of Palliative Care. In: Rose FC, ed. ALS: from Charcot to the Present and into the Future. London: Smith-Gordon & Company Ltd; 1994:315-324.

• Gresham LS, Molgaard CA, Smith RA. Induction of cytochrome P-450 enzymes via tobacco smoke: a potential mechanism for developing resistance to environmental toxins as related to parkinsonism and other neurologic diseases. Neuroepidemiology. 1993;12(2):114-116. 

• Smith RA, Melmed S, Sherman B, Frane J, Munsat TL, Festoff BW. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve. 1993;16(6):624-633. 

• Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther. 1992;51(6):647-655. 

• Rose C, Valderhaug KL, Wedlund PJ. The Excitotoxin Hypothesis: Therapeutic Considerations in Amyotrophic Lateral Sclerosis. In: Norris FH, ed. Motor Neurone Disease. London: Smith-Gordon Publishers; 1990:287-293.

• Eldon MA, Smith RA, Leese PT, Daigle AE, Katz DV, Richieri SP. Safety and tolerability of single intravenous doses of T cell modulatory peptide (TCMP-80) in healthy volunteers. J Clin Pharmacol. 1990;30(4):352-357. 

• Norris FH, Smith RA. The Treatment of Amyotrophic Lateral Sclerosis with Interferon. In: Smith RA, ed. Interferon Treatment of Neurologic Disorders. New York: Marcel Dekker; 1988:265-276.

• Wills RJ, Smith RA. Pharmacokinetics of Interferons. In: Smith RA, ed. Interferon Treatment of Neurologic Disorders. New York: Marcel Dekker; 1988:103-133.

• Lakshmanan J, Burns C, Smith RA. Molecular forms of nerve growth factor in mouse submaxillary glands. Biochem Biophys Res Commun. 1988;152(3):1008-1014. 

• Norris F, Smith RA. Caring for Patients with Amyotrophic Lateral Sclerosis. In: Carash L, Lovelace R, eds. Psychosocial Aspects of Muscular Dystrophy and Allied Diseases. Springfield: Charles C. Thomas Publishers; 1987:23-30.

• Gresham LS, Molgaard CA, Golbeck AL, Smith R. Amyotrophic lateral sclerosis and history of skeletal fracture: a case-control study. Neurology. 1987;37(4):717-719. 

• Gresham LS, Molgaard CA, Golbeck AL, Smith R. Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case-control study. Neuroepidemiology. 1986;5(1):29-38. 

• Panitch HS, Gomez-Plascencia J, Norris FH, Cantell K, Smith RA. Subacute sclerosing panencephalitis: remission after treatment with intraventricular interferon. Neurology. 1986;36(4):562-566. 

• Norris FH, Smith RA, Denys EH. Motor neurone disease: towards better care. Br Med J (Clin Res Ed). 1985;291(6490):259-262.

• Smith RA, Norris F, Palmer D, Bernhardt L, Wills RJ. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther. 1985;37(1):85-88.

• Brahic M, Smith RA, Gibbs CJ Jr, Garruto RM, Tourtellotte WW, Cash E. Detection of picornavirus sequences in nervous tissue of amyotrophic lateral sclerosis and control patients. Ann Neurol. 1985;18(3):337-343. 

• Cudkowitz ME, Brown RH, Smith RA. Free Radical Toxicity in Amyotrophic Lateral Sclerosis. In: Shaw CA, ed. Glutathione in the Nervous System. New York: Taylor & Francis; 1998:343-353.

• Smith RA, Gillie E, Licht L. Palliative Treatment of Motor Neuron Disease. In: De Jong  JM, ed. Diseases of the Motor System (Handbook of Clinical Neurology). Amsterdam: Elsevier Science Publishers; 1991:459-473.

• Smith RA. Experimental Treatment of Amyotrophic Lateral Sclerosis. In: Smith RA, ed. Handbook of Amyotrophic Lateral Sclerosis. New York: Marcel Dekker; 1991:317-343.

• Smith RA, Jacoby S, Festoff B, Melmed S, Frane J, Sherman B. The Influence of Compliance and Other Human Factors On Treatment Trials. In: Rose FD, ed. Methodological Problems in ALS Trials. New York: Demos Publications; 1990.

• Margolis RS, Whitten R, Rauch CT, Hassain H, Smith RA. Characterization of Microtubule Associated Proteins in Amyotrophic Lateral Sclerosis. In: Tsubake T, Yase Y, eds. Amyotrophic Lateral Sclerosis, Research Aspects. Amsterdam: Elsevier Science Publishers; 1988:325-332.

• Smith RA, Landel CP, Cornelius CE, Revel M. Mapping the Action of Interferon on Primate Brain. In: Cantell K, Schellekens H, eds. The Biology of the Interferon System 1986. Amsterdam: Elsevier Science Publishers; 1987:563-566.

• Smith RA. On Behalf of the Patient. In: Research, Psychological and Treatment Aspects of ALS. Amsterdam: Elsevier Science Publishers; 1987:319-322.

• Smith RA, Norris FH. Antiviral Therapy. In: Research, Psychological and Treatment Aspects of ALS. Amsterdam: Elsevier Science Publishers; 1987:297-304.

• Smith RA, Abramsky O, Steiner I, Panitch H, Cantell K. The Experimental Treatment of Subacute Sclerosing Panencephalitis with Interferon. In: Stewart WE, Schellekens H, eds. The Biology of the Interferon System. Amsterdam: Elsevier Science Publishers; 1986:505-510.

• Salazar AM, Gibbs CJ, Gajdusek DC, Smith RA. Clinical Usage of Interferons: Central Nervous System Disorders. In: Came PE, Carter WA, eds. Interferons and Their Applications. Vol 71. Handbook of Experimental Pharmacology. Springer, Berlin, Heidelberg; 1984:471-497.

• ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology. 1996;46(5):1244-1249.

​

Books

• Neurotherapeutics in the Era of Translational Medicine, R.A. Smith, C.N. Svendsen, B.K. Kaspar (Eds.), Elsevier Academic Press, 2021.

• Handbook of Amyotrophic Lateral Sclerosis, R.A. Smith (Ed.), Marcel Dekker, New York, 1992.

• Interferon Treatment of Neurologic Disorders, R.A. Smith (Ed.), Marcel Dekker, New York, 1988.

​

​

​

​